Related content

Pharmacogenomics of &bgr;β₂-agonist: key focus on signaling pathways

By Bhatnagar Pallav   Guleria Randeep   Kukreti Ritushree  

Pharmacogenomics, Vol. 7, Iss. 6, 2006-09 ,pp. : 919-933

Future Medicine

Access to resources Recommend Favorite

GRK5 Gln41Leu polymorphism is not associated with sensitivity to &bgr;β₁-adrenergic blockade in humans

By Kurnik Daniel   Cunningham Andrew J   Sofowora Gbenga G   Kohli Utkarsh   Li Chun   Friedman Eitan A   Muszkat Mordechai   Menon Usha B   Wood Alastair JJ   Stein C Michael  

Pharmacogenomics, Vol. 10, Iss. 10, 2009-10 ,pp. : 1581-1587

Future Medicine

Access to resources Recommend Favorite

Role of pharmacogenetics in variable response to drugs: focus on opioids

By Kadiev Esin   Patel Vipul   Rad Pouya   Thankachan Lovely   Tram Abby   Weinlein Meg   Woodfin Kristin   Raffa Robert B   Nagar Swati  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 4, Iss. 1, 2008-01 ,pp. : 77-91

Informa Healthcare

Access to resources Recommend Favorite

Clinical consequences of ADR&bgr;β2 polymorphisms

By Hawkins Gregory A   Weiss Scott T   Bleecker Eugene R  

Pharmacogenomics, Vol. 9, Iss. 3, 2008-03 ,pp. : 349-358

Future Medicine

Access to resources Recommend Favorite

Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia – an update

By Scharfetter Joachim  

Pharmacogenomics, Vol. 5, Iss. 6, 2004-09 ,pp. : 691-698

Future Medicine

Access to resources Recommend Favorite